- Home
- RVSB vs NTHI Comparison
RVSB vs NTHI Comparison
Compare RVSB & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVSB | NTHI |
|---|---|---|
| Founded | 1923 | 2008 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9M | 114.6M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | RVSB | NTHI |
|---|---|---|
| Price | $5.39 | $3.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | ★ $15.00 |
| AVG Volume (30 Days) | 54.3K | ★ 54.6K |
| Earning Date | 04-28-2026 | 05-19-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.74 | $3.01 |
| 52 Week High | $6.22 | $12.99 |
Technical Indicators
Market Signals| Indicator | RVSB | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 39.45 |
| Support Level | $5.24 | $3.01 |
| Resistance Level | $5.56 | $4.59 |
| Average True Range (ATR) | 0.11 | 0.23 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 64.86 | 47.76 |
Price Performance
Historical ComparisonAbout RVSB Riverview Bancorp Inc
Riverview Bancorp Inc is the bank holding company. The Company's operations are managed along two operating segments, consisting of banking operations performed by the Bank and trust and investment services performed by the Trust Company. The Bank is engaged mainly in the business of attracting deposits from the general public and using such funds, together with other borrowings, to make various commercial business, commercial real estate, land, multi-family real estate, real estate construction and consumer loans. Additionally, the Trust Company offers trust and investment services. It has single operating segment.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.